Galmed Develops New Aramchol ODF for Parkinson's, Targets $6B Market

Galmed Pharmaceuticals announced significant progress in developing an orally dispersible film (ODF) formulation of its SCD1 inhibitor, Aramchol, for Parkinson's disease. This new ODF formulation demonstrates approximately 150% higher systemic bioavailability and approximately 300% increased CNS exposure compared to conventional oral administration. The formulation aims to improve patient convenience and adherence by addressing dysphagia, a common issue in Parkinson's patients, and targets a $6 billion market, positioning Aramchol's PD program as an ideal out-licensing candidate.